Shared on 01 Nov 25
Analysts have increased their price target for Ocular Therapeutix from $20 to $29, citing the newly derisked pivotal program in Nonproliferative Diabetic Retinopathy and anticipated value from upcoming wet AMD trial results as justification for their greater optimism. Analyst Commentary Recent analyst discussions have centered on the positive momentum surrounding Ocular Therapeutix due to its progress in developing treatments for retinal diseases.
Shared on 17 Oct 25
Fair value Increased 8.68%Future Drug Approvals Will Expand Retinal Disease Treatments
Ocular Therapeutix saw its analyst price target increase significantly from $20 to $29, as analysts cite newly available de-risked data in Nonproliferative Diabetic Retinopathy and upcoming pivotal readouts in wet AMD as key drivers of enhanced valuation. Analyst Commentary Following the recent price target revision, analysts have weighed in with both optimistic and cautious perspectives regarding Ocular Therapeutix's outlook.
Shared on 03 Oct 25
Fair value Increased 16%Future Drug Approvals Will Expand Retinal Disease Treatments
Analysts have raised their fair value estimate for Ocular Therapeutix from $17.45 to $20.17 per share, citing increased clarity around the company's pivotal program in Nonproliferative Diabetic Retinopathy and its emerging opportunities in wet AMD. Analyst Commentary Analysts have provided detailed insights following recent developments at Ocular Therapeutix, offering a balanced perspective on both the opportunities and challenges influencing the company's valuation and future growth prospects.
Shared on 01 May 25
Fair value Increased 6.82%Future Drug Approvals Will Expand Retinal Disease Treatments
Shared on 24 Apr 25
FDA Approval And Adjusted Trials Will Expand Treatment Options
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
FDA Approval And Adjusted Trials Will Expand Treatment Options
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 0.25%FDA Approval And Adjusted Trials Will Expand Treatment Options
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 9.02%FDA Approval And Adjusted Trials Will Expand Treatment Options
AnalystConsensusTarget has decreased revenue growth from 43.3% to 29.3%, increased future PE multiple from 100.5x to 127.6x and increased shares outstanding growth rate from 0.0% to 0.0%.
Shared on 26 Mar 25
Fair value Increased 2.87%